Compare NMFC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMFC | SPRY |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 796.4M | 829.3M |
| IPO Year | N/A | 2020 |
| Metric | NMFC | SPRY |
|---|---|---|
| Price | $7.81 | $8.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $8.63 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 1.4M | 959.2K |
| Earning Date | 01-01-0001 | 06-12-2026 |
| Dividend Yield | ★ 16.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $91.00 |
| P/E Ratio | $12.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.52 | $6.66 |
| 52 Week High | $11.20 | $18.63 |
| Indicator | NMFC | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 37.85 | 41.71 |
| Support Level | $7.52 | $8.61 |
| Resistance Level | $8.28 | $10.44 |
| Average True Range (ATR) | 0.23 | 0.46 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 39.71 | 40.74 |
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.